Tarsus Pharmaceuticals Appoints David Pyott to its Board of Directors

Published on February 20, 2026
IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a biopharmaceutical company focused on the development and commercialization of therapeutic eyecare treatments, has announced the appointment of David E. I. Pyott, a leader in the global biopharmaceutical industry and former chairman and CEO of Allergan, Inc., to its board of directors, effective immediately. Pyott brings decades of global leadership experience spanning innovative R&D, product development, and commercial execution, according to the announcement. During his 17-year tenure as CEO of Allergan, Pyott transformed the company from a focused eyecare business with approximately $1 billion in sales into a global specialty pharmaceutical and medical device leader generating more than $7 billion in revenue, the announcement said.
Continue reading on website
Other news

Carl Zeiss Meditec Reports First-Quarter Results, Cites ‘Weak Start’ to Fiscal Year 2025/26

February 20, 2026
JENA, Germany—Carl Zeiss Meditec has announced its first-quarter fiscal 2025/26 financial results, reporting revenue of €467 million for the first quarter, down 4.8 percent year-over-year, as compared with €490.5 million for the same period the prior year. EBITA amounted to €8.1 million, compared with €35.2 million the prior year, with the EBITA margin coming in at 1.7 percent vs 7.2 percent the p

Top Business and Health Care Experts to Explore the Power of ‘Resilience Rising’ at VM Summit

February 20, 2026
NEWARK, N.J.—Vision Monday’s 2026 Leadership Summit titled, “Resilience Rising: Future-Proofing Your Business for the 21st Century,” will analyze what resilience means to today’s eyecare leaders and will offer attendees the opportunity to learn which big ideas and trends are slated to make an impact on their businesses, practices and the optical industry. The VM summit, an exclusive annual event f